Tests Tune-401 safety in adults with chronic hepatitis B
Tests the new Tune-401 treatment for safety in adults with chronic hepatitis B.
Key facts
- Who runs it
- Tune Therapeutics, Inc.
- Where
- Auckland, New ZealandSee the siteAlso in 2 other countries, 2 sites
- Trial code
- Registry title
- Phase 1b, Open-label Study of Tune-401 to Assess Safety, PK and PD in Adults With Chronic Hepatitis B
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 36 people, planned
- Started
- 29 Nov 2024
- Expected to end
- 30 Oct 2028
- Type of study
- Interventional, 2 groups
- Treatments tested
- Tune-401
- Record updated
- 6 January 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with chronic hepatitis B who are already taking a nucleos(t)ide analogue medicine.
- Age
- 18 to 75 years
- Sex
- Men and women can join.
- Disease stage
- Chronic hepatitis B infection. HBeAg can be negative or positive.
- Earlier treatment
- People must be taking a nucleos(t)ide analogue.
- Biomarker or test result
- HBeAg-negative or HBeAg-positive. Body mass index (BMI) of 18.5 kg/m² or more at screening.
Main reasons for not taking part
- ALT/AST of 1.5 × the upper limit of normal (ULN) or more together with total bilirubin of 1.5 × ULN or more
- Any sign or history of liver disease not caused by hepatitis B virus
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- M/F, BMI ≥ 18.5 kg/m² at screening, age 18-75, inclusive
- Diagnosed with Chronic Hepatitis B
- On nucleos(t)ide analogue
- HBeAg-negative or positive
Who cannot take part
- Participants with any evidence or history of liver disease of non-HBV etiology
- ALT/ AST ≥ 1.5 × upper limit of normal (ULN) and total bilirubin ≥ 1. 5 × ULN
- Other protocol defined Inclusion/Exclusion criteria may apply
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
This trial is currently available in New Zealand.
Also in 2 other countries, 2 sites
- New Zealand Clinical ResearchAuckland, New ZealandContact: New Zealand Clinical ResearchTaking people
About the trial
What the trial wants to find out
This study will be conducted to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of Tune-401 in adult participants with Chronic Hepatitis B.
The 2 groups in the trial
- Tune-401 Part I : Single Ascending DoseTreatment being tested
Epigenetic gene silencing system delivered by lipid nanoparticles (LNPs) for intravenous (IV) administration
Treatment: Tune-401
- Tune-401 Part II :Single/Finite Multiple DoseTreatment being tested
Epigenetic gene silencing system delivered by lipid nanoparticles (LNPs) for intravenous (IV) administration
Treatment: Tune-401
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Phase 1b Multicenter, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Tune-401 in Participants With Chronic Hepatitis B Infection
- Plain-language title
- Tests Tune-401 safety in adults with chronic hepatitis BGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Criteria questions
- Built from NCT06671093, who can take part
- Record updated
- 6 January 2026